NewEdge Advisors LLC Has $5 Million Position in Becton, Dickinson and Company $BDX

NewEdge Advisors LLC cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 25.0% during the second quarter, Holdings Channel reports. The institutional investor owned 33,016 shares of the medical instruments supplier’s stock after selling 11,016 shares during the quarter. NewEdge Advisors LLC’s holdings in Becton, Dickinson and Company were worth $4,996,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of BDX. Squarepoint Ops LLC grew its stake in Becton, Dickinson and Company by 2,758.1% during the second quarter. Squarepoint Ops LLC now owns 253,485 shares of the medical instruments supplier’s stock worth $38,360,000 after buying an additional 244,616 shares during the last quarter. Ramsay Stattman Vela & Price Inc. lifted its stake in Becton, Dickinson and Company by 2.7% in the second quarter. Ramsay Stattman Vela & Price Inc. now owns 27,487 shares of the medical instruments supplier’s stock valued at $4,160,000 after buying an additional 713 shares during the period. Allworth Financial LP grew its holdings in shares of Becton, Dickinson and Company by 10.4% in the 2nd quarter. Allworth Financial LP now owns 15,164 shares of the medical instruments supplier’s stock valued at $2,295,000 after buying an additional 1,433 shares during the period. Arizona State Retirement System lifted its stake in Becton, Dickinson and Company by 1.2% in the second quarter. Arizona State Retirement System now owns 79,086 shares of the medical instruments supplier’s stock valued at $11,968,000 after buying an additional 970 shares in the last quarter. Finally, Empirical Finance LLC lifted its stake in Becton, Dickinson and Company by 3.4% in the 2nd quarter. Empirical Finance LLC now owns 10,076 shares of the medical instruments supplier’s stock valued at $1,525,000 after acquiring an additional 327 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on BDX shares. UBS Group initiated coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target for the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a report on Monday, July 6th. Piper Sandler upped their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Finally, Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $187.67.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 8,005 shares of company stock valued at $1,423,580. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Up 3.0%

Becton, Dickinson and Company stock opened at $183.21 on Tuesday. The firm has a market cap of $50.48 billion, a price-to-earnings ratio of 55.18, a PEG ratio of 12.53 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The firm has a 50 day moving average price of $173.06 and a two-hundred day moving average price of $160.49. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the business posted $3.68 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD’s products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.